Regeneron/Sanofi's Dupixent Approval Signals Major Treatment ...
1 day ago · Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA’s (NASDAQ: SNY) Dupixent recently gained FDA approval for COPD, marking its sixth U.S. indication since its first use for atopic ...
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a …
2 days ago · The Phase III BOREAS trial demonstrated that patients treated with DUPIXENT experienced a 30% reduction in moderate-to-severe exacerbations over 52 weeks, significant improvements in lung function ...
Dupixent approved in the US as the first-ever biologic medicine …
Sep 27, 2024 · Dupixent has a proven track record as a first-in-class medicine, providing benefit to the many patients suffering from type 2 inflammatory related diseases such as asthma and atopic dermatitis.
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in …
Oct 24, 2024 · Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status. Confirmatory data to support U.S. regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 years. More than 300,000 people in the U.S. suffer from chronic ...
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
Nov 7, 2024 · SNY. REGN. The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one. The approval extends the use ...
Sanofi’s Dupixent Gains EU Approval for Pediatric Eosinophilic ...
Nov 7, 2024 · Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with eosinophilic esophagitis, expanding its market potential and offering new hope for young ...
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve ...
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial. Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with ...
Dupixent® late-breaking data from NOTUS confirmatory phase 3 …
May 20, 2024 · NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease …
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine …
Jun 7, 2022 · Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy through adulthood.
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a …
2 days ago · Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight PR Newswire Tue, Nov 12, 2024, 5:31 PM 10 ...
- Some results have been removed